BR100 Increased By (0.19%)
BR30 Increased By (0.57%)
KSE100 Increased By (0.46%)
KSE30 Increased By (0.55%)
AGHA 6.47 Increased By ▲ 0.15 (2.37%)
BECO 4.37 Increased By ▲ 0.10 (2.34%)
BML 62.18 Decreased By ▼ -0.27 (-0.43%)
BOP 31.55 Increased By ▲ 0.32 (1.02%)
CNERGY 11.69 Increased By ▲ 0.10 (0.86%)
CSIL 5.93 Increased By ▲ 0.21 (3.67%)
FCCL 60.90 Decreased By ▼ -0.64 (-1.04%)
FFL 14.75 Decreased By ▼ -0.27 (-1.8%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.29 Increased By ▲ 0.03 (0.48%)
KOSM 5.96 Increased By ▲ 0.40 (7.19%)
LOTCHEM 24.80 Increased By ▲ 0.12 (0.49%)
MLCF 103.07 Decreased By ▼ -1.01 (-0.97%)
NBP 174.00 Decreased By ▼ -1.28 (-0.73%)
NCPL 52.50 Decreased By ▼ -0.27 (-0.51%)
NPL 54.20 Increased By ▲ 0.08 (0.15%)
OGDC 317.10 Increased By ▲ 3.71 (1.18%)
PACE 9.35 Increased By ▲ 0.15 (1.63%)
PAEL 35.46 Decreased By ▼ -0.34 (-0.95%)
PIBTL 13.77 Increased By ▲ 0.30 (2.23%)
PPL 227.05 Increased By ▲ 5.24 (2.36%)
PRL 80.11 Increased By ▲ 1.03 (1.3%)
PTC 46.95 Increased By ▲ 0.10 (0.21%)
SSGC 24.00 Increased By ▲ 0.13 (0.54%)
TBL 9.29 Decreased By ▼ -0.02 (-0.21%)
TELE 7.65 Increased By ▲ 0.26 (3.52%)
TPL 24.85 Decreased By ▼ -0.26 (-1.04%)
TPLP 12.86 Increased By ▲ 0.35 (2.8%)
TREET 25.95 Decreased By ▼ -0.30 (-1.14%)
TRG 53.20 Decreased By ▼ -0.24 (-0.45%)

The world's largest producer of homeopathy treatments said Wednesday that it would cut 646 jobs in France, or around a fourth of its workforce in the country, after French authorities slashed reimbursements to patients for the alternative remedies.

Boiron Laboratories also said it would shutter 13 of its 31 sites in France, including one of three production labs, following a 13 percent drop in French sales last year.

The company had warned that jobs were at risk after the government cut the refunds paid by French social security from 30 percent to 15 percent starting this year, before they are eliminated completely in 2021.

The move came after France's National Authority for Health (HAS) concluded last June that there was no benefit to homeopathy, saying it had "not scientifically demonstrated sufficient effectiveness to justify a reimbursement."

Agnes Buzyn, the health minister at the time and herself a doctor, soon announced the phase-out of reimbursements that had once been on a par with standard drugs, at 65 percent.

Other European governments have also halted or curtailed their payouts to clients who opt for homeopathic treatments, which are based on the idea that a substance that causes certain symptoms can also help alleviate them.

"For the past two years, the virulent, unjustified and repeated attacks against homeopathy in France have weighed heavily on our company, which has seen its activity and economic results decline sharply," Boiron said in a statement.

Copyright Agence France-Presse, 2020

Comments

Comments are closed for this article.